91Â鶹ÌìÃÀÖ±²¥

Journal Article

1. Franklin, Achtyes, Altinay, Bailey, Bhati, Carr, Conroy, Husain, Khurshid, Lencz, McDonald, Mickey BJ, Murrough, Nestor, Nickl-Jockschat, Nikayin, Reeves, Reti, Selek, Sanacora, Trapp, Viswanath, Wright, Sullivan, Zandi, Potash (2025). Genetics of Response to ECT, TMS, ketamine and esketamine. Am J Hum Genet, in press.
2. Jawish R, Shangraw K, Charles JE, Eddington B, Worden J, Tak C, Mickey BJ, Gordon AJ, Smid MC (2025). Interest in Transcranial Magnetic Stimulation (TMS) Therapy for Treatment of Depression and Substance Use Disorder Among Peripartum Individuals. J Addict Med, in press.
3. Rush AJ, Conway CR, Aaronson ST, George MS, Riva-Posse P, Dunner DL, Zajecka J, Bunker MT, Quevedo J, Allen RM, Alva G, Luing H, Nahas Z, Manu L, Bennett JI, Mickey BJ, Becker J, Sheline Y, Cusin C, Murrough JW, Reeves K, Rosenquist PB, Lee YL, Majewski S, Way J, Olin B, Sackeim HA (2024). Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. Brain Stimul, 18(3), 690-700. ()
4. Conway CR, Aaronson ST, Sackeim HA, George MS, Zajecka J, Bunker MT, Duffy W, Stedman M, Riva-Posse P, Allen RM, Quevedo J, Berger M, Alva G, Malik MA, Dunner DL, Cichowicz I, Banov M, Manu L, Nahas Z, Macaluso M, Mickey BJ, Sheline Y, Kriedt CL, Lee YL, Gordon C, Shy O, Tran Q, Yates L, Rush AJ (2024). Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. Brain Stimul, 18(3), 676-689. ()
5. Riis TS, Feldman DA, Kwon SS, Vonesh LC, Koppelmans V, Brown JR, Solzbacher D, Kubanek J, Mickey BJ (2024). Noninvasive Modulation of the Subcallosal Cingulate and Depression With Focused Ultrasonic Waves. Biol Psychiatry, 97(8), 825-834. ()
6. Franklin CE, Achtyes E, Altinay M, Bailey K, Bhati MT, Carr BR, Conroy SK, Husain MM, Khurshid KA, Lencz T, McDonald WM, Mickey BJ, Murrough J, Nestor S, Nickl-Jockschat T, Nikayin S, Reeves K, Reti IM, Selek S, Sanacora G, Trapp NT, Viswanath B, Wright JH, Sullivan P, Zandi PP, Potash JB (2024). The genetics of severe depression. Mol Psychiatry, 30(3), 1117-1126. ()
7. Thurston MD, Ericksen LC, Jacobson MM, Bustamante A, Koppelmans V, Mickey BJ, Love TM (2024). Oxytocin differentially modulates reward system responses to social and non-social incentives. Psychopharmacology (Berl), 242(3), 449-460. ()
8. Feldman DA, Jones KG, Vonesh LC, Jacobs R, Hoffman N, Lybbert C, Huang J, Kuck K, Odell D, Tadler SC, Mickey BJ (2024). Immediate effects of propofol on mood: a randomized comparison of two doses in a cohort with depression. Psychopharmacology (Berl), 242(3), 481-495. ()
9. Trapp NT, Purgianto A, Taylor JJ, Singh MK, Oberman LM, Mickey BJ, Youssef NA, Solzbacher D, Zebley B, Cabrera LY, Conroy S, Cristancho M, Richards JR, Flood MJ, Barbour T, Blumberger DM, Taylor SF, Feifel D, Reti IM, McClintock SM, Lisanby SH, Husain MM, National Network of Depression Centers Neuromodulation Task Group (2024). Consensus review and considerations on TMS to treat depression: A comprehensive update endorsed by the National Network of Depression Centers, the Clinical TMS Society, and the International Federation of Clinical Neurophysiology. Clin Neurophysiol, 170, 206-233. ()
10. Provenza NR, Reddy S, Allam AK, Rajesh SV, Diab N, Reyes G, Caston RM, Katlowitz KA, Gandhi AD, Bechtold RA, Dang HQ, Najera RA, Giridharan N, Kabotyanski KE, Momin F, Hasen M, Banks GP, Mickey BJ, Kious BM, Shofty B, Hayden BY, Herron JA, Storch EA, Patel AB, Goodman WK, Sheth SA (2024). Disruption of neural periodicity predicts clinical response after deep brain stimulation for obsessive-compulsive disorder. Nat Med, 30(10), 3004-3014. ()
11. Conway CR, Aaronson ST, Sackeim HA, Duffy W, Stedman M, Quevedo J, Allen RM, Riva-Posse P, Berger MA, Alva G, Malik MA, Dunner DL, Cichowicz I, Luing H, Zajecka J, Nahas Z, Mickey BJ, Kablinger AS, Kriedt CL, Bunker MT, Lee YL, Shy O, Majewski S, Olin B, Tran Q, Rush AJ (2024). Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report. Brain Stimul, 17(2), 448-459. ()
12. Riis T, Feldman D, Losser A, Mickey B, Kubanek J (2024). Device for Multifocal Delivery of Ultrasound Into Deep Brain Regions in Humans. IEEE Trans Biomed Eng, 71(2), 660-668. ()
13. Riis TS, Feldman DA, Mickey BJ, Kubanek J (2024). Controlled noninvasive modulation of deep brain regions in humans. Commun Eng, 3, 13.
14. Nunez NA, Joseph B, Kumar R, Douka I, Miola A, Prokop LJ, Mickey BJ, Singh B (2023). An Update on the Efficacy of Single and Serial Intravenous Ketamine Infusions and Esketamine for Bipolar Depression: A Systematic Review and Meta-Analysis. Brain Sci, 13(12). ()
15. Lybbert C, Huang J, Jones KG, Mickey BJ, Tadler S, Odell D, Stanford J, Kuck K (2023). Clinical validation of an adapted Eleveld Model for high-dose propofol treatments for depression. J Clin Monit Comput, 37(5), 1369-1377. ()
16. Silcox JW, Mickey B, Payne BR (2023). Disruption to left inferior frontal cortex modulates semantic prediction effects in reading and subsequent memory: Evidence from simultaneous TMS-EEG. Psychophysiology, 60(9), e14312. ()
17. Shah SB, Peddada TN, Song C, Mensah M, Sung H, Yavi M, Yuan P, Zarate CA Jr, Mickey BJ, Burmeister M, Akula N, McMahon FJ (2023). Exome-wide association study of treatment-resistant depression suggests novel treatment targets. Sci Rep, 13(1), 12467. ()
18. Jones KG, Lybbert C, Euler MJ, Huang J, Lunt S, Richards SV, Jessop JE, Larson A, Odell DH, Kuck K, Tadler SC, Mickey BJ (2023). Diversity of electroencephalographic patterns during propofol-induced burst suppression. Front Syst Neurosci, 17, 1172856. ()
19. Oka F, Weischedel K, Bakian A, Mickey BJ (2022). Treatment-Resistant Mood Disorders in LGBTQ People: A Retrospective Study of Clinical Features and Response to Electroconvulsive Therapy. J Clin Psychiatry, 83(4). ()
20. Baker AK, Ericksen LC, Koppelmans V, Mickey BJ, Martucci KT, Zubieta JK, Love TM (2022). Altered Reward Processing and Sex Differences in Chronic Pain. Front Neurosci, 16, 889849. ()
21. Langenecker SA, Westlund Schreiner M, Thomas LR, Bessette KL, DelDonno SR, Jenkins LM, Easter RE, Stange JP, Pocius SL, Dillahunt A, Love TM, Phan KL, Koppelmans V, Paulus M, Lindquist MA, Caffo B, Mickey BJ, Welsh RC (2021). Using Network Parcels and Resting-State Networks to Estimate Correlates of Mood Disorder and Related Research Domain Criteria Constructs of Reward Responsiveness and Inhibitory Control. Biol Psychiatry Cogn Neurosci Neuroimaging, 7(1), 76-84. ()
22. Mickey BJ, Ginsburg Y, Jensen E, Maixner DF (2021). Distinct predictors of short- versus long-term depression outcomes following electroconvulsive therapy. J Psychiatr Res, 145, 159-166. ()
23. Warthen KG, Welsh RC, Sanford B, Koppelmans V, Burmeister M, Mickey BJ (2021). Neuropeptide Y Variation Is Associated With Altered Static and Dynamic Functional Connectivity of the Salience Network. Front Syst Neurosci, 15, 629488. ()
24. Lex H, Nevers SW, Jensen EL, Ginsburg Y, Maixner DF, Mickey BJ (2021). Long-term quality of life in treatment-resistant depression after electroconvulsive therapy. J Affect Disord, 291, 135-139. ()
25. Pierson MD, Mickey BJ, Gilley LB, Weeks HR III (2021). Outcomes of Youth Treated With Electroconvulsive Therapy: A Retrospective Cohort Study. J Clin Psychiatry, 82(2). ()
26. Hsu DT, Sankar A, Malik MA, Langenecker SA, Mickey BJ, Love TM (2020). Common neural responses to romantic rejection and acceptance in healthy adults. Soc Neurosci, 15(5), 571-583. ()
27. Warthen KG, Boyse-Peacor A, Jones KG, Sanford B, Love TM, Mickey BJ (2020). Sex differences in the human reward system: convergent behavioral, autonomic and neural evidence. Soc Cogn Affect Neurosci, 15(7), 789-801. ()
28. Soda T, McLoughlin DM, Clark SR, Oltedal L, Kessler U, Haavik J, Bousman C, Smith DJ, Bioque M, Clements CC, Loo C, Vila-Rodriguez F, Minelli A, Mickey BJ, Milev R, Docherty AR, Langan Martin J, Achtyes ED, Arolt V, Redlich R, Dannlowski U, Cardoner N, Clare E, Craddock N, Di Florio A, Dmitrzak-Weglarz M, Forty L, Gordon-Smith K, Husain M, Ingram WM, Jones L, Jones I, Juruena M, Kirov G, Landn M, Mller DJ, Nordenskld A, Plsson E, Paul M, Permoda A, Pliszka B, Rea J, Schubert KO, Sonnen JA, Soria V, Stageman W, Takamiya A, Urretavizacaya M, Watson S, Zavorotny M, Young AH, Vieta E, Rybakowski JK, Gennarelli M, Zandi PP, Sullivan PF, Baune BT (2019). International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). Eur Arch Psychiatry Clin Neurosci, 270(7), 921-932. ()
29. DelDonno SR, Mickey BJ, Pruitt PJ, Stange JP, Hsu DT, Weldon AL, Zubieta JK, Langenecker SA (2019). Influence of childhood adversity, approach motivation traits, and depression on individual differences in brain activation during reward anticipation. Biol Psychol, 146, 107709. ()
30. Sankar A, Yttredahl AA, Fourcade EW, Mickey BJ, Love TM, Langenecker SA, Hsu DT (2019). Dissociable Neural Responses to Monetary and Social Gain and Loss in Women With Major Depressive Disorder. Front Behav Neurosci, 13, 149. ()
31. Langenecker SA, Klumpp H, Peters AT, Crane NA, DelDonno SR, Bessette KL, Ajilore O, Leow A, Shankman SA, Walker SJ, Ransom MT, Hsu DT, Phan KL, Zubieta JK, Mickey BJ, Stange JP (2018). Multidimensional imaging techniques for prediction of treatment response in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 91, 38-48. ()
32. Langenecker SA, Mickey BJ, Eichhammer P, Sen S, Elverman KH, Kennedy SE, Heitzeg MM, Ribeiro SM, Love TM, Hsu DT, Koeppe RA, Watson SJ, Akil H, Goldman D, Burmeister M, Zubieta JK (2019). Cognitive Control as a 5-HT1A-Based Domain That Is Disrupted in Major Depressive Disorder. Front Psychol, 10, 691. ()
33. Warthen KG, Sanford B, Walker K, Jones KG, Angstadt M, Sripada C, Goldman D, Zubieta JK, Welsh RC, Burmeister M, Mickey BJ (2019). Neuropeptide Y and representation of salience in human nucleus accumbens. Neuropsychopharmacology, 44(3), 495-502. ()
34. Lex H, Ginsburg Y, Sitzmann AF, Grayhack C, Maixner DF, Mickey BJ (2019). Quality of life across domains among individuals with treatment-resistant depression. J Affect Disord, 243, 401-407. ()
35. Kang GE, Mickey BJ, Krembs BS, McInnis MG, Gross MM (2019). The effect of mood phases on balance control in bipolar disorder. J Biomech, 82, 266-270. ()
36. Kious BM, Bakian A, Zhao J, Mickey B, Guille C, Renshaw P, Sen S (2019). Altitude and risk of depression and anxiety: findings from the intern health study. Int Rev Psychiatry, 31(7-8), 637-645. ()
37. Mickey BJ, White AT, Arp AM, Leonardi K, Torres MM, Larson AL, Odell DH, Whittingham SA, Beck MM, Jessop JE, Sakata DJ, Bushnell LA, Pierson MD, Solzbacher D, Kendrick EJ, Weeks HR 3rd, Light AR, Light KC, Tadler SC (2018). Propofol for Treatment-Resistant Depression: A Pilot Study. Int J Neuropsychopharmacol, 21(12), 1079-1089. ()
38. Kang GE, Mickey BJ, McInnis MG, Krembs BS, Gross MM (2018). Motor behavior characteristics in various phases of bipolar disorder revealed through biomechanical analysis: Quantitative measures of activity and energy variables during gait and sit-to-walk. Psychiatry Res, 269, 93-101. ()
39. Mickey BJ, Ginsburg Y, Sitzmann AF, Grayhack C, Sen S, Kirschbaum C, Maixner DF, Abelson JL (2018). Cortisol trajectory, melancholia, and response to electroconvulsive therapy. J Psychiatr Res, 103, 46-53. ()
40. Tadler SC, Mickey BJ (2018). Emerging evidence for antidepressant actions of anesthetic agents. Curr Opin Anaesthesiol, 31(4), 439-445. ()
41. Yttredahl AA, McRobert E, Sheler B, Mickey BJ, Love TM, Langenecker SA, Zubieta JK, Hsu DT (2018). Abnormal emotional and neural responses to romantic rejection and acceptance in depressed women. J Affect Disord, 234, 231-238. ()
42. Pecina M, Sikora M, Avery ET, Heffernan J, Pecina S, Mickey BJ, Zubieta JK (2017). Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response. Eur Neuropsychopharmacol, 27(10), 977-986. ()
43. Crane NA, Jenkins LM, Bhaumik R, Dion C, Gowins JR, Mickey BJ, Zubieta JK, Langenecker SA (2017). Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain, 140(2), 472-486. ()
44. Mickey BJ, Heffernan J, Heisel C, Pecia M, Hsu DT, Zubieta JK, Love TM (2016). Oxytocin modulates hemodynamic responses to monetary incentives in humans. Psychopharmacology (Berl), 233(23-24), 3905-3919. ()
45. Tadayonnejad R, Ajilore O, Mickey BJ, Crane NA, Hsu DT, Kumar A, Zubieta JK, Langenecker SA (2016). Pharmacological modulation of pulvinar resting-state regional oscillations and network dynamics in major depression. Psychiatry Res Neuroimaging, 252, 10-18. ()
46. Jacobs RH, Barba A, Gowins JR, Klumpp H, Jenkins LM, Mickey BJ, Ajilore O, Pecina M, Sikora M, Ryan KA, Hsu DT, Welsh RC, Zubieta JK, Phan KL, Langenecker SA (2016). Decoupling of the amygdala to other salience network regions in adolescent-onset recurrent major depressive disorder. Psychol Med, 46(5), 1055-67. ()
47. Gluskin BS, Mickey BJ (2016). Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. Transl Psychiatry, 6, e747. ()
48. Sikora M, Heffernan J, Avery ET, Mickey BJ, Zubieta JK, Pecia M (2015). Salience Network Functional Connectivity Predicts Placebo Effects in Major Depression. Biol Psychiatry Cogn Neurosci Neuroimaging, 1(1), 68-76. ()
49. DelDonno SR, Weldon AL, Crane NA, Passarotti AM, Pruitt PJ, Gabriel LB, Yau W, Meyers KK, Hsu DT, Taylor SF, Heitzeg MM, Herbener E, Shankman SA, Mickey BJ, Zubieta JK, Langenecker SA (2015). Affective personality predictors of disrupted reward learning and pursuit in major depressive disorder. Psychiatry Res, 230(1), 56-64. ()
50. Pecina M, Bohnert AS, Sikora M, Avery ET, Langenecker SA, Mickey BJ, Zubieta JK (2015). Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression. JAMA Psychiatry, 72(11), 1087-94. ()
51. Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015). Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry, 76(10), 1374-84. ()
52. Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, Mickey BJ, Koeppe RA, Langenecker SA, Zubieta JK (2015). It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder. Mol Psychiatry, 20(2), 193-200. ()
53. Glaser YG, Zubieta JK, Hsu DT, Villafuerte S, Mickey BJ, Trucco EM, Burmeister M, Zucker RA, Heitzeg MM (2014). Indirect effect of corticotropin-releasing hormone receptor 1 gene variation on negative emotionality and alcohol use via right ventrolateral prefrontal cortex. J Neurosci, 34(11), 4099-107. ()
54. Lohoff FW, Hodge R, Narasimhan S, Nall A, Ferraro TN, Mickey BJ, Heitzeg MM, Langenecker SA, Zubieta JK, Bogdan R, Nikolova YS, Drabant E, Hariri AR, Bevilacqua L, Goldman D, Doyle GA (2014). Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry, 19(1), 129-39. ()
55. Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Wang H, Ni L, Walker SJ, Mickey BJ, Korycinski ST, Koeppe RA, Crocker JK, Langenecker SA, Zubieta JK (2013). Response of the mu-opioid system to social rejection and acceptance. Mol Psychiatry, 18(11), 1211-7. ()
56. Pecia M, Mickey BJ, Love T, Wang H, Langenecker SA, Hodgkinson C, Shen PH, Villafuerte S, Hsu D, Weisenbach SL, Stohler CS, Goldman D, Zubieta JK (2013). DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience. Cortex, 49(3), 877-90. ()
57. Love TM, Enoch MA, Hodgkinson CA, Pecina M, Mickey B, Koeppe RA, Stohler CS, Goldman D, Zubieta JK (2012). Oxytocin gene polymorphisms influence human dopaminergic function in a sex-dependent manner. Biol Psychiatry, 72(3), 198-206. ()
58. Mickey BJ, Sanford BJ, Love TM, Shen PH, Hodgkinson CA, Stohler CS, Goldman D, Zubieta JK (2012). Striatal dopamine release and genetic variation of the serotonin 2C receptor in humans. J Neurosci, 32(27), 9344-50. ()
59. Hsu DT, Mickey BJ, Langenecker SA, Heitzeg MM, Love TM, Wang H, Kennedy SE, Pecia M, Shafir T, Hodgkinson CA, Enoch MA, Goldman D, Zubieta JK (2012). Variation in the corticotropin-releasing hormone receptor 1 (CRHR1) gene influences fMRI signal responses during emotional stimulus processing. J Neurosci, 32(9), 3253-60. ()
60. Mickey BJ, Zhou Z, Heitzeg MM, Heinz E, Hodgkinson CA, Hsu DT, Langenecker SA, Love TM, Pecia M, Shafir T, Stohler CS, Goldman D, Zubieta JK (2011). Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry, 68(2), 158-66. ()
61. Mickey BJ, Ducci F, Hodgkinson CA, Langenecker SA, Goldman D, Zubieta JK (2008). Monoamine oxidase A genotype predicts human serotonin 1A receptor availability in vivo. J Neurosci, 28(44), 11354-9. ()

Book Chapter

1. Hristidis VC, Nagele P, Palanca BJ, Tadler SC, Mickey BJ, Gott BM, Conway CR (2024). The Use of Inhaled Gases in Psychiatry. In Quevedo, Brunoni, Hamani (Eds.), Interventional Psychiatry (pp. 383-401). Academic Press.
2. Conway CR, Mickey BJ, Palanca BJ, Tadler SC, Nagele P (2022). Inhaled Gases for Treatment-Resistant Major Depression. In Quevedo, Riva-Posse, Bobo (Eds.), Managing Treatment-Resistant Depression (pp. 481-491). Academic Press.
3. Sen S, Mickey BJ, Greden JF (2011). Psychopharmacological Roadmap for Treatment Resistant Depression. In Greden, et al (Eds.), Treatment Resistant Depression (pp. 33-49). American Psychiatric Publishing, Inc.

Commentary

1. Mickey BJ (2016). Genetic variation and the D2 dopamine receptor: implications for the treatment of neuropsychiatric disease. Pharmacogenomics, 17(11), 1207-1210. ()

Case Report

1. Jawish R, Smid M, Gordon A, Shangraw K, Mickey BJ (2024). Prolonged transcranial magnetic stimulation in a pregnant patient with treatment-resistant depression: a case report. J Med Case Rep, 18(1), 512. ()
2. Riis TS, Feldman DA, Vonesh LC, Brown JR, Solzbacher D, Kubanek J, Mickey BJ (2023). Durable effects of deep brain ultrasonic neuromodulation on major depression: a case report. J Med Case Rep, 17(1), 449. ()
3. Durns T, Rich B, Benson C, Mickey BJ, Weischedel K (2020). A Case of biopharmaceutical-induced catatonia and the implication of a novel mechanism. J ECT, 36(3), e29.

News

• Translational Research Building to Facilitate New Era for Mental Health in Utah and Beyond

Podcasts

• What to do When Depression or Bipolar Disorder Treaments are not Working